Adult GlioblastomaPhase 1NCT04573140Papers
Autologous total tumor mRNA
RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
What the film says
Recurrent glioblastoma resists nearly everything, partly because it bathes itself in TGF-beta, which puts immune cells to sleep, and because patients' steroids quiet them further.
The idea: natural killer cells edited so that neither signal can reach them, delivered straight into the tumor.
At MD Anderson, natural killer cells from donated umbilical cord blood are expanded and gene-edited to remove two receptors: the TGF-beta receptor, and the receptor for glucocorticoid steroids. They are then injected through a small reservoir under the scalp directly into the tumor, every four weeks, up to eight. In some patients, a dose comes before planned surgery, so the removed tissue shows whether the cells arrived and survived.
Shiao-Pei Weathers leads it, from age twelve. Public record; not medical advice.
Sources behind this film
Cord blood-derived, expanded, allogeneic NK; TGF-βR2 and NR3C1 (glucocorticoid receptor) deleted; Intratumoral via Ommaya every four weeks, up to 8 doses (Group 1); Group 2: dose two weeks before resection; tissue analyzed for NK persistence; Ages ≥12; Shiao-Pei Weathers; MD Anderson
The drug
Given CB-NK-TGF-betaR2-/NR3C1- intratumorally
PRIMARY OBJECTIVES: * To determine the safety and tolerability of intratumoral injection of escalating doses of allogeneic CB-NK-TGF-£]R2-/NR3C1- in patients with recurrent grade 4 astrocytoma, * To determine the maximum tolerated dose (MTD) and the occurrence of dose limiting toxicities (DLTs) (Group 1) of CB-NK-TGF-£]R2-/NR3C1- administered via IT injection in patients with recurrent grade 4 astrocytoma * To evaluate the immunological phenotype and anti-tumor function of NK cells in resected tumor tissue after treatment with CB-NK-TGF-âR2-/NR3C1- in the surgical expansion group (Group 2).
Persistency of the NK cells in the tissue will be assessed by flow cytometry. Tissue cells will be stained with anti human CD45, anti human CD56 and anti HLA molecule expressed by the cord blood donor infused in the patient. NK cells from the tissue may be isolated using magnetic bead selection (anti-HLA specific from cord blood donor labeled with PE and them use a anti PE magnetics bead selection).
The study
This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 and NR3C1 (cord blood [CB]-NK-TGF-betaR2-/NR3C1-) in treating patients with glioblastoma that has come back (recurrent). CB-NK-TGF-betaR2-/NR3C1- cells are genetically changed immune cells that may help to control the disease.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.